Next Article in Journal
Challenges in the Classification of Cardiac Arrhythmias and Ischemia Using End-to-End Deep Learning and the Electrocardiogram: A Systematic Review
Previous Article in Journal
Anatomy-Guided Hybrid CNN–ViT Model with Neuro-Symbolic Reasoning for Early Diagnosis of Thoracic Diseases Multilabel
Previous Article in Special Issue
A Comparative Study of Radiofrequency Ablation, Microwave Ablation, and Percutaneous Ethanol Injection in Treatment of Hepatocellular Carcinoma—A Single-Center Experience
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Diagnostics
Volume 16
Issue 1
10.3390/diagnostics16010160
diagnostics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

The Role of Aurora Kinase A in HBV-Associated Hepatocellular Carcinomas: A Molecular and Immunohistochemical Study

by
Mustafa Huz
1,*,
Nese Karadag Soylu
1,
Ahmet Koc
2,
Zeynep Kucukakcali
3,
Nefsun Danis
2 and
Onural Ozhan
4
1
Department of Medical Pathology, Faculty of Medicine, Inonu University, Malatya 44050, Türkiye
2
Department of Medical Genetics, Faculty of Medicine, Inonu University, Malatya 44050, Türkiye
3
Biostatistics and Medical Informatics A.D., Faculty of Medicine, Inonu University, Malatya 44050, Türkiye
4
Department of Medical Pharmacology, Faculty of Medicine, Inonu University, Malatya 44050, Türkiye
*
Author to whom correspondence should be addressed.
Diagnostics 2026, 16(1), 160; https://doi.org/10.3390/diagnostics16010160
Submission received: 9 December 2025 / Revised: 30 December 2025 / Accepted: 31 December 2025 / Published: 4 January 2026
(This article belongs to the Special Issue Hepatocellular Carcinoma: Diagnosis and Management)
Browse Figures
Versions Notes

Abstract

Objectives: Although Aurora kinase A (AURKA) expression has been investigated in many cancer types, studies focusing on its role in hepatitis B virus-associated hepatocellular carcinoma (HBV-HCC) are limited. In this study, we examined the activity of AURKA and its substrates (PLK1, P53, and BRCA1) in HBV-HCC and cryptogenic hepatocellular carcinoma (Cr-HCC) cases. Methods: The study groups consisted of HBV-HCC, Cr-HCC, and healthy liver tissue cases. AURKA copy number variation (CNV) was analyzed using molecular methods. AURKA expression was evaluated by molecular and immunohistochemical (IHC) methods. AURKA substrates P53Ser315, PLK1Thr210, and BRCA1 were also analyzed by IHC. Results: There was no increase in AURKA gene copy number among the groups (2−∆∆Ct < 2). AURKA level was significantly increased in both test groups (p < 0.001). At the protein level, AURKA was significantly higher in both cancer groups compared to the control group (p < 0.001). Phospho-P53Ser315 levels were significantly higher in both HBV-HCC and Cr-HCC groups compared to the control group (p = 0.002 and p < 0.001, respectively). Cr-HCC cases also showed significantly higher levels compared to HBV-HCC (p = 0.025). For phospho-PLK1Thr210, Cr-HCC cases showed statistically higher expression compared to both the control group and HBV-HCC cases (p = 0.001).

1. Introduction

Hepatocellular carcinoma (HCC) is the most common histological subtype of primary liver cancer and remains one of the leading causes of cancer-related mortality worldwide. Although substantial progress has been made in understanding the epidemiology and molecular mechanisms of HCC, targeted and personalized therapeutic strategies are still limited [1,2]. Protein kinases, including members of the Aurora kinase family, have emerged as critical mediators of oncogenesis and as important therapeutic targets in cancer drug development [3,4,5].
Recent advances in systemic therapy for HCC, particularly the introduction of immune checkpoint inhibitors and combinations such as atezolizumab plus bevacizumab, have demonstrated superior overall survival outcomes and reshaped first-line treatment standards [6,7,8]. Furthermore, approaches integrating locoregional therapies with systemic agents, including transarterial chemoembolization (TACE)-based strategies, are being investigated to optimize therapeutic benefit in selected patient populations [7,8,9,10].
Aurora kinases, members of the serine/threonine kinase family, play essential roles in regulating the cell division cycle. AURKA, which phosphorylates multiple kinases and phosphatases, influences diverse cellular processes including cell cycle progression, centrosome regulation, bipolar spindle formation, and chromosome segregation [11,12]. During mitosis, AURKA-mediated phosphorylation triggers mitotic entry, whereas substrate dephosphorylation marks mitotic exit. Key AURKA substrates include Polo-like kinase 1 (PLK1), p53, and breast cancer type 1 susceptibility protein (BRCA1) [13,14]. AURKA and PLK1, both highly expressed during the G2/M phase, act synergistically by promoting CDC2 activation through positive feedback regulation. Overexpression of AURKA enables cells to bypass the G2 DNA-damage checkpoint, resulting in centrosome amplification and genomic instability features commonly observed across multiple cancer types. Collectively, these findings support the hypothesis that AURKA, through overexpression or impaired inhibition, may function as an oncogene [11,12,15].
In HBV-related HCC, the hepatitis B viral protein HBx interacts with and binds to p53, thereby suppressing key tumor-suppressive mechanisms [12,16,17,18]. Overexpression of AURKA has been shown to destabilize p53 through Ser315 phosphorylation, leading to loss of function, centrosome amplification, chromosomal instability, and oncogenic transformation, whereas AURKA inhibition stabilizes p53 and induces G2/M cell cycle arrest [17,19].
PLK1, a major substrate of AURKA, is a critical mitotic kinase that regulates several key steps in cell division [19,20,21]. Numerous studies have shown that PLK1 phosphorylation is essential for mitotic entry. AURKA directly phosphorylates the Thr210 residue within the PLK1 kinase domain, initiating mitotic progression [21,22,23,24]. A DNA-damage response is initiated at the centrosome following genomic insult, mediated by BRCA1, which coordinates DNA repair in the nucleus and prevents centrosome overduplication. Loss or mutation of BRCA1 has been associated with centrosome amplification and mitotic spindle abnormalities in cancer cells. BRCA1 has been reported to regulate centrosome homeostasis by binding to and phosphorylating AURKA [25].
In this study, we included HCC cases associated with HBV etiology as well as cryptogenic HCC (Cr-HCC) cases, which lack a clinically or serologically identifiable cause. This design enabled a more comprehensive interpretation of the findings. We investigated AURKA kinase activity on key substrates, including p53, PLK1, and BRCA1, alongside AURKA expression levels and gene copy-number alterations.

2. Materials and Methods

2.1. Creation of Study Protocol and Selection of Cases

The experimental groups were formed as follows: The first group (control group) consisted of liver samples from healthy living donors undergoing living-donor liver transplantation, whose livers were confirmed as histopathologically normal. The second group (HBV-HCC) included cases diagnosed with HBV-related hepatocellular carcinoma (HBV-HCC). The third group (Cr-HCC) comprised cases of cryptogenic hepatocellular carcinoma (Cr-HCC), which were serologically and clinically unrelated to any known etiology (Table 1).
Based on a power analysis, the total sample size was determined as be 51 cases, with a minimum of 17 cases per group. Cases were randomly selected retrospectively from archival records from 2021, with no restrictions on age or gender. For HBV-HCC cases with immunohistochemical (IHC) staining results showing HBV positivity (>30%) were preferred.
Hematoxylin-eosin-stained slides from all cases were re-evaluated. Tumor representative areas were selected for the preparation of paraffin blocks using the tissue microarray (TMA) technique. TMA paraffin block tissues, 3 mm in diameter, were utilized for molecular testing and IHC analysis [26]. The TMA blocks were prepared using a Harris Uni-Core Size: 3.0 punch (Electron Microscopy Sciences, Cat. 69036-30).
The expression level and copy number variation (CNV) of the AURKA gene were analyzed using molecular techniques. Downstream substrates of AURKA, including P53, PLK1, and BRCA-1, were examined using immunohistochemistry (IHC). Phospho-specific antibodies targeting AURKA-activated molecules, such as Phospho-PLK1Thr210 and Phospho-p53Ser315, were selected for analysis [17,27]. Given the challenges of performing gene expression analysis on formalin-fixed paraffin-embedded (FFPE) tissues, IHC-based analysis of AURKA was established as a contingency plan (Plan B) [28].

2.2. Molecular Genetic Analyzes

AURKA gene expression and copy number variation (CNV) were analyzed using SYBR Green-based quantitative PCR. The human single-copy gene 36B4 was used as the reference gene, and specific primers were designed for both gene expression and CNV analysis (Table 2).
For gene expression analysis, 8 µm sections taken from TMA blocks of formalin-fixed paraffin-embedded (FFPE) liver tissues were transferred into 1.5 mL tubes, and RNA extraction was performed using the Monarch Total RNA Miniprep Kit (Cat. No: NEB #T2010, New England Biolabs, Ipswich, MA, USA). Sections were processed through xylene-based deparaffinization, ethanol washes, enzymatic digestion, and column-based RNA purification according to the manufacturer’s protocol. RNA quality was assessed via gel electrophoresis (1% gel, 80 V for 50 min), which revealed no intact band formation under UV light, indicating RNA fragmentation (Figure 1). Despite this, cDNA synthesis proceeded using the ProtoScript First Strand cDNA Synthesis Kit (Cat. No: E6560S, New England Biolabs, Ipswich, MA, USA).
For CNV analysis, 8 µm sections were obtained from FFPE tissue blocks, deparaffinized, and processed using the Quick-DNA FFPE Miniprep Kit (Cat. No: D3067, Zymo Research, Irvine, CA, USA). DNA quality control was performed using a NanoDrop spectrophotometer (ND-1000, Thermo Scientific, Waltham, MA, USA), and samples with an A260/A280 ratio of 1.8–2.0 were included in the analysis. A total of 200 ng DNA was used per reaction, with 10 µL Master Mix, 0.5 µL primer, 0.1 µL SYBR Green, and nuclease-free water added to each well. Real-time PCR was performed in triplicate using the Gotaq qPCR Master Mix Kit (Cat. No: A6001, Promega, Madison, WI, USA) for 40 cycles.
CNV analysis was conducted on the StepOnePlus Real-Time PCR System (Applied Biosystems, Waltham, MA, USA), and results were evaluated using the relative quantification method.

2.3. Immunohistochemical Analysis

Tissue microarray (TMA) paraffin blocks were sectioned at 4 µm using a microtome (RM2255, Leica Biosystems, Nussloch, Germany). Antigen retrieval and subsequent steps were performed on an automated IHC platform (Dako Omnis, Agilent, Santa Clara, CA, USA) following standard protocols. Primary antibodies included AURKA (1:100, GeneTex, Hsinchu City, Taiwan), Phospho-p53Ser315 (1:100, GeneTex, Taiwan), and BRCA1 (1:200, Elabscience, Houston, TX, USA), incubated for 30 min. For Phospho-PLK1Thr210 (1:100, Affinity Biosciences, Changzhou, China), low-pH antigen retrieval was applied, followed by a 60 min incubation. Detection was performed using the EnVision FLEX system (Agilent Dako, Santa Clara, CA, USA). DAB chromogen was applied, and slides were counterstained with hematoxylin for 10 min.
Stained slides were evaluated in two dimensions under a light microscope (Olympus BX53). Staining intensity was defined by color depth and assigned a semi-quantitative score (0–4). Staining prevalence (positivity rate) was defined as the percentage of positive TMA tissue area and assigned a semi-quantitative score (0–3). The scores from the two parameters were multiplied to obtain a final score ranging from 0 to 12 (Table 3) [29].
Two independent pathologists evaluated the IHC results. In cases where scoring differed, slides were re-examined jointly and a consensus score was reached.

2.4. Statistical Analysis

The Shapiro–Wilk test was used to assess the normality of the data. For numerical values that did not follow a normal distribution, the Mann–Whitney U test was applied for statistical analysis. Data were summarized as median (minimum-maximum). A p-value of <0.05 was considered statistically significant. All analyses were performed using IBM SPSS Statistics version 26.0.

3. Results

3.1. AURKA Gene Expression

In the AURKA gene expression study, spectrophotometric measurement and agarose gel electrophoresis following RNA isolation indicated RNA fragmentation (Figure 1).
RNA extracted from FFPE liver tissues showed no distinct 28S and 18S rRNA bands, indicating RNA degradation and unsuitability for gene expression analysis. The small panel shows a reference RNA sample run on a separate gel to illustrate the intact 28S and 18S bands expected in high-quality RNA.
The gel electrophoresis image was obtained from normal liver tissue samples (Control group). Despite fragmented RNA, cDNA synthesis and RT-PCR were performed as planned; however, no cDNA amplification was observed and no Ct values were generated, consistent with the RNA quantification and gel electrophoresis findings. These results confirm the known challenges of performing gene expression analysis on FFPE tissue samples, particularly those derived from hepatectomy specimens. Accordingly, AURKA expression was evaluated at the protein level by IHC, in line with the predefined contingency strategy (Plan B).

3.2. AURKA Gene Copy Number Variation

When HBV-HCC and Cr-HCC groups were compared with the control group, the 2−ΔΔCt values were found to be <2 in both groups, indicating no increase in AURKA copy number relative to normal liver tissue. When the HBV-HCC and Cr-HCC groups were compared to each other after undergoing identical pre-analytical and analytical processing the 2−ΔΔCt value was 2.11. However, this difference was not statistically significant (Table 4), confirming that no measurable copy number variation was present between the two HCC subtypes.

3.3. Immunohistochemical Markers Findings

Tissue sections from TMA paraffin blocks were stained using immunohistochemistry (IHC) to evaluate protein expression of AURKA, P53Ser315, PLK1Thr210, and BRCA1. Staining extent and intensity were assessed by light microscopy.
AURKA immunostaining showed nuclear localization, consistent with its known role in centrosome and mitotic spindle regulation, but cytoplasmic staining was observed, particularly in conditions suggestive of microtubule stress or repair [30,31]. In the Control group, weak nuclear and cytoplasmic staining was detected in pericentral hepatocytes in a subset of cases likely reflecting early cytotoxic and enzymatic exposure in this zone while the remaining samples showed no staining. HBV-HCC cases exhibited diffuse nuclear staining accompanied by cytoplasmic positivity, whereas Cr-HCC cases demonstrated stronger, more widespread, and more heterogeneous staining patterns (Figure 2).
P53Ser315 staining was evaluated in the nucleus, cytoplasm, and mitochondrial matrix. In the Control group, five cases showed sparse and weak nuclear staining, while no staining was observed in eleven cases. HBV-HCC cases demonstrated predominantly moderate to weak staining, with one case showing two distinct staining intensities suggestive of tumor heterogeneity. Cr-HCC cases displayed strong nuclear staining in four samples, while the remaining cases exhibited moderate to weak staining (Figure 2).
PLK1Thr210 staining localized primarily to centrosomes, centromeres, and kinetochores in the nucleus, as well as to cytoskeletal structures in the cytoplasm. In the Control group, weak to moderate pericentral hepatocyte staining was observed in four cases. Eight HBV-HCC cases demonstrated no staining, and the remaining cases showed weak staining. In contrast, Cr-HCC samples generally exhibited moderate to strong staining, with four cases demonstrating intense diffuse positivity (Figure 2).
The results were summarized through statistical analysis and are presented in Table 5.

4. Discussion

In HCC developing on a cirrhotic background, diagnosis is often based on characteristic dynamic contrast-enhanced CT/MRI features and is standardized through the Liver Imaging Reporting and Data System (LI-RADS) framework. In at-risk cirrhotic patients, lesions meeting major imaging criteria and categorized as LI-RADS 5 are considered diagnostic of HCC, and biopsy is usually not required. This strategy is clinically justified given biopsy-related bleeding and needle-tract tumor seeding risks, as well as the possibility of false-negative results due to sampling limitations. However, biopsy remains relevant in non-cirrhotic patients, in indeterminate LI-RADS 3–4 observations, or when histologic, molecular, or immunophenotypic characterization is needed to guide management; the principal indications are summarized in Table 6 [32,33,34,35].
Beyond radiological diagnostic criteria, genomic alterations provide an additional biological framework for understanding hepatocellular carcinoma. In contrast to point mutations, copy number variations (CNVs) represent larger-scale genomic alterations that can influence gene dosage and expression levels. The impact of CNVs on oncogene amplification and transcriptional activity has been demonstrated across multiple cancer types [36,37]. For instance, hepatocellular carcinoma (HCC) frequently exhibits 2 to 10 fold amplification of oncogenes such as Cyclin D1, CDKN1A, KRAS, and MDM2 [32,38]. Although AURKA amplification has been reported in colorectal and breast cancers, prior work detected CNV in only three of 224 hepatitis B virus-negative HCC cases [37,38,39].
In our study, when comparing HBV-HCC and Cr-HCC cases to the Control group, no increase in AURKA copy number was observed (2−ΔΔCt < 2). Comparisons between HBV-HCC and Cr-HCC groups, both derived from hepatectomy specimens processed under similar pre-analytical conditions, yielded a 2−ΔΔCt value of 2.11, which was not statistically significant (p = 0.060). Mean Ct values for the reference gene were comparable in HBV-HCC and Cr-HCC (21.99 and 21.56, respectively), whereas the Control group demonstrated an earlier Ct value (20.98). This difference likely reflects the use of hepatectomy-derived tissue microarray samples in the two HCC groups. These findings are consistent with previous reports showing no significant AURKA CNV in HCC. However, inherent limitations, including sample variability and pre-analytical factors such as cold ischemia time, tissue size, and processing conditions, may have influenced the results [32,38].
Overexpression of AURKA has been reported particularly in colorectal adenocarcinoma, non-small cell lung cancer, and ovarian cancer, and has been associated with poor prognosis and treatment resistance [40]. Recently, the AURKA inhibitor MLN8237 (Alisertib) entered clinical trials, and experimental studies have demonstrated that MLN8237 exhibits a strong synergistic effect with Sorafenib in HCC models [41,42]. AURKA expression was analyzed on a protein level using immunohistochemistry (IHC) since RNA of adequate quality could not be obtained from the TMA tissue series. The inability to obtain high-quality RNA was correlated with the duration of cold ischemia in cases and was thus discussed under the “Study Limiting Factors” section.
Summarizing the IHC staining results, the AURKA-specific antibody demonstrated moderate to strong staining in the nuclei and cytoplasm of HBV-HCC and Cr-HCC cases, whereas half of the control samples showed no staining and the remaining exhibited only weak cytoplasmic staining. AURKA’s major function is related to centrosome regulation and spindle assembly during mitosis; however, cytoplasmic staining has been reported under cellular stress conditions due to its auxiliary role in microtubule organization [30,31].
When comparing HBV-HCC and Cr-HCC cases with the control group, AURKA immunoreactivity (including both nuclear and cytoplasmic staining patterns) was significantly higher in both tumor groups (p < 0.001). No significant difference was observed between HBV-HCC and Cr-HCC (p = 0.224). This staining pattern aligns with previous studies demonstrating increased AURKA activity in malignant tissues compared with non-tumoral liver tissue [43,44,45].
AURKA regulates the function of its substrates including tumor suppressor genes and oncogenes involved in mitosis through AURKA-mediated phosphorylation [17]. Three of these substrates (P53, PLK1, and BRCA-1) were analyzed in this study. The activity and functional relevance of AURKA on these molecules were evaluated across HBV-HCC, Cr-HCC, and Control groups.
AURKA has been shown to phosphorylate P53 at Ser315, leading to its ubiquitination by MDM2 and subsequent proteolysis. Under physiological conditions, P53 is not degraded in the presence of MDM2 if AURKA activity is low or absent. However, when MDM2 is mutated or AURKA is overexpressed as demonstrated in our study phosphorylation of P53 at Ser315 destabilizes P53 and disrupts checkpoint-mediated responses, thereby promoting oncogenic transformation [17,19,46,47].
In the Control group, phospho-P53Ser315 staining was absent in most cases, with only sporadic weak nuclear staining observed. In contrast, HBV-HCC and Cr-HCC cases exhibited marked P53Ser315 positivity, and both demonstrated statistically significant differences compared with the Control group (p = 0.002 and p < 0.001, respectively). Cr-HCC cases also differed significantly from HBV-HCC (p = 0.025). Although phosphorylated P53Ser315 was elevated in both HCC groups, staining intensity was greater in Cr-HCC. This finding suggests that P53 destabilization via AURKA-mediated phosphorylation, and its interaction with the P53-MDM2 axis, may differ mechanistically between HBV-HCC and Cr-HCC. These results imply that therapeutic approaches targeting AURKA overexpression may yield distinct clinical benefits depending on the underlying etiology, potentially offering greater therapeutic value in Cr-HCC.
PLK1, another key substrate of AURKA, is typically overexpressed in tumor cells. AURKA directly phosphorylates PLK1 at the conserved Thr210 residue within its activation loop, a modification essential for PLK1 activation. Without Thr210 phosphorylation, PLK1 remains inactive despite its association with target proteins [20,48,49,50]. Balanced PLK1 activity is required for proper cell proliferation and mitotic progression, and dysregulation particularly aberrant down-regulation has been associated with carcinogenesis [51]. Activation of PLK1 is necessary for progression through the G2/M checkpoint, and AURKA-mediated phosphorylation of Thr210 has been shown to promote mitotic entry [22,24,49,50,52].
In this study, a phospho-specific PLK1Thr210 antibody was used to assess the relationship between AURKA and PLK1. Cr-HCC cases demonstrated pronounced nuclear PLK1Thr210 staining, whereas no staining was observed in the Control group except for weak pericentral cytoplasmic staining in a few hepatocytes. This pericentral pattern is consistent with early liver injury due to zone 3 exposure to metabolic stress and toxic substances [53]. Statistically, PLK1Thr210 expression was significantly higher in Cr-HCC than in the Control group (p < 0.001) and HBV-HCC (p = 0.001). However, no significant difference was observed between HBV-HCC and Control groups (p = 0.296). These findings indicate that PLK1 activation differs by etiology and may be more relevant in Cr-HCC pathogenesis.
Overexpressed PLK1 undergoes degradation via the endonuclease-G pathway, leading to apoptosis, highlighting its relevance as a therapeutic target [49,50]. In our study, PLK1 phosphorylated at Thr210 an activation event mediated by AURKA was observed exclusively in Cr-HCC cases, whereas HBV-HCC tissues showed minimal phosphorylated PLK1. This divergence between p53Ser315 upregulation in HBV-HCC and PLK1Thr210 activation in Cr-HCC suggests distinct oncogenic programs driving the two subtypes.
Given that PLK1 inhibitors require phosphorylated, active PLK1 to exert their therapeutic effect, the absence of PLK1Thr210 in HBV-HCC may limit the utility of PLK1-directed therapies in this subgroup [24,25,52]. In contrast, the presence of activated PLK1 in Cr-HCC indicates a potentially actionable therapeutic axis in this etiology. However, functional evidence directly confirming the biological consequences of PLK1Thr210 activation in Cr-HCC such as its role in proliferation, tumorigenesis, or therapy response is currently lacking. Therefore, while our data suggest that targeting active PLK1 may hold therapeutic promise specifically in Cr-HCC, further mechanistic studies are required to validate and translate this approach [24].
In the evaluation of BRCA1 staining, HBV-HCC cases demonstrated significantly higher expression compared to the Control group (p = 0.006). However, no significant difference was observed between Cr-HCC and the Control group (p = 0.239), nor between the two tumor groups (HBV-HCC vs. Cr-HCC; p = 0.110). AURKA, localized to the centrosome, facilitates the G2/M transition through its kinase activity. Importantly, inactivation of BRCA1 also a centrosomal protein has been associated with loss of the G2/M checkpoint and increased AURKA phosphorylation [54].
Although both HCC groups showed similarly elevated AURKA expression, the BRCA1 results suggest a distinct regulatory pattern in HBV-HCC. In HBV-HCC, high AURKA expression appears sufficient to drive mitotic progression despite BRCA1 presence, supporting prior reports that AURKA overexpression can override BRCA1 mediated genomic surveillance and promote cell cycle progression even under DNA damage conditions [25,45,46].
Our findings suggest that AURKA may represent a potential therapeutic target, particularly in HBV-HCC and Cr-HCC, tumor subtypes characterized by genomic instability and dysregulated mitotic control. While AURKA and its substrate, PLK1, inhibitors have been extensively investigated in preclinical models and early-phase clinical studies in other malignancies, accumulating evidence indicates that their application in hepatocellular carcinoma has so far remained largely limited to preclinical and early translational settings, rather than routine clinical integration [15,17,20,42,55,56,57].
In Cr-HCC, increased AURKA expression accompanied by phosphorylation of PLK1 at Thr210 supports a disease mechanism predominantly driven by aberrant mitotic control [20,24]. In contrast, HBV-associated tumors demonstrated more pronounced alterations in p53 phosphorylation (via Ser315) and BRCA1-related pathways, consistent with disruption of DNA damage checkpoint regulation [16,20,24,46,49,52,56]. From a clinical perspective, these findings suggest that AURKA-targeted strategies may require etiological stratification, with PLK1-centered approaches potentially being more relevant in Cr-HCC, whereas therapeutic strategies focusing on the p53/BRCA1 axis may be more applicable in HBV-associated disease.
In the next five years, we anticipate increased research on the development of biomarker-guided treatment strategies targeting AURKA and PLK1 related pathways, driven by advances in precision oncology approaches, a better understanding of immune-metabolic signaling pathways, and high-resolution profiling of tumor biology. We believe this approach could complement emerging systemic treatment modalities and contribute to improved clinical outcomes in patients with advanced HCC.

Factors Limiting the Study

Formalin-fixed paraffin-embedded (FFPE) liver tissue offers valuable archival material for molecular studies; however, sample processing conditions can significantly affect nucleic acid integrity. Consistent with previous reports, prolonged formalin exposure, large tissue volume, and intraoperative transfer delays likely contributed to the RNA fragmentation observed in our samples (Figure 1). Additionally, factors such as storage duration, processing variability, and cold ischemia in donor liver specimens may have further impaired RNA quality, preventing reliable transcript-level analysis even in control samples [53]. For this reason, molecular evaluation in our study relied primarily on immunohistochemistry and phospho-protein assessment rather than RNA-based assays.
The study also has biological and methodological limitations. Our findings suggest differences in AURKA-dependent downstream signaling pathways between Cr-HCC and HBV-HCC; however, these observations are based on a single-center cohort and require confirmation in larger, multicenter series. Additionally, while the clinical context of the cases was similar, variables such as age, sex, tumor stage, and liver function status were not analytically controlled, highlighting the need for validation in larger and clinically stratified cohorts. Furthermore, although PLK1 phosphorylation was detected in Cr-HCC and p53/BRCA1 modulation in HBV-HCC, functional studies involving AURKA inhibition and PLK1 modulation are needed to demonstrate whether AURKA directly mediates these effects. Finally, our study does not directly correlate with clinical outcomes; therefore, further studies evaluating mechanistic analyses in conjunction with clinical data will be necessary to determine the translational relevance of the observed pathway differences.

5. Conclusions

AURKA expression was found to be elevated in both HBV-HCC and Cr-HCC cases, consistent with reports in various other cancer types. However, the activity of AURKA on its downstream substrates (P53Ser315, PLK1Thr210, and BRCA1) differed between the two tumor groups. These findings suggest that AURKA-associated signaling pathways may operate through distinct molecular mechanisms in the initiation and progression of carcinogenesis in HBV-HCC and Cr-HCC.
AURKA-mediated phosphorylation of PLK1Thr210 was observed at a higher level in Cr-HCC cases than in HBV-HCC cases. Given the limited use of cytotoxic agents in HCC, antisense oligonucleotide mediated PLK1 inhibition has been proposed as a promising therapeutic strategy [19,49]. Based on our findings, targeting the active, phosphorylated form of PLK1 in Cr-HCC may provide greater therapeutic benefit than in HBV-HCC, where PLK1Thr210 activation was minimal. The intense nuclear staining pattern observed with the PLK1Thr210 phospho-specific antibody in Cr-HCC suggests that PLK1Thr210 may serve as a potential biomarker for this subgroup. Additionally, no alterations in AURKA gene copy number were detected in either HBV-HCC or Cr-HCC cases.
Our findings should be supported by future studies to further clarify the role and mechanisms of AURKA in HCC. A key limitation of this study is that all samples were obtained from a single institution, which may introduce bias related to demographic and regional characteristics and limit the generalizability of the results. Therefore, multicenter studies with larger and more diverse cohorts are needed to validate and extend these findings.

Author Contributions

The conceptualization, design, and experimental leadership of the study were carried out in a joint effort by M.H., A.K. and N.K.S. Again, M.H., A.K. and N.K.S. conducted the data analysis. M.H. and N.K.S. collected the clinical samples and information. M.H. and N.D. were responsible for sample processing and implementing the experimental method. Statistical analysis was performed by Z.K. The manuscript was written by M.H., A.K. and O.O. All authors have read and agreed to the published version of the manuscript.

Funding

This research was supported by Inonu University Scientific Research Projects Unit with project number 2021/2713.

Institutional Review Board Statement

This study was conducted in accordance with the Declaration of Helsinki and was approved by the Malatya Clinical Research Ethics Committee (No: 2021/171, date of approval 8 September 2021).

Informed Consent Statement

The informed consent was waived due to the nature of retrospective study. Permission to use the dataset for the purposes of the study was obtained from the head of the Department of Medical Pathology, Inönü University, Turgut Ozal Medical Centre.

Data Availability Statement

The original contributions presented in this study are included in the article. Further inquiries can be directed to the corresponding author.

Conflicts of Interest

The author declares no conflicts of interest in this study.

References

  1. Llovet, J.M.; Kelley, R.K.; Villanueva, A.; Singal, A.G.; Pikarsky, E.; Roayaie, S.; Lencioni, R.; Koike, K.; Zucman-Rossi, J.; Finn, R.S. Hepatocellular carcinoma. Nat. Rev. Dis. Prim. 2021, 7, 6. [Google Scholar] [CrossRef]
  2. McGlynn, K.A.; Petrick, J.L.; El-Serag, H.B. Epidemiology of Hepatocellular Carcinoma. Hepatology 2021, 73, 4–13. [Google Scholar] [CrossRef] [PubMed]
  3. Mishra, D.; Mishra, A.; Rai, S.N.; Vamanu, E.; Singh, M.P. Identification of Prognostic Biomarkers for Suppressing Tumorigenesis and Metastasis of Hepatocellular Carcinoma through Transcriptome Analysis. Diagnostics 2023, 13, 965. [Google Scholar] [CrossRef]
  4. Bhullar, K.S.; Lagarón, N.O.; McGowan, E.M.; Parmar, I.; Jha, A.; Hubbard, B.P.; Rupasinghe, H.P.V. Kinase-targeted cancer therapies: Progress, challenges and future directions. Mol. Cancer 2018, 17, 48. [Google Scholar] [CrossRef]
  5. Roskoski, R. A historical overview of protein kinases and their targeted small molecule inhibitors. Pharmacol. Res. 2015, 100, 1–23. [Google Scholar] [CrossRef] [PubMed]
  6. Rizzo, A.; Ricci, A.D. Challenges and Future Trends of Hepatocellular Carcinoma Immunotherapy. Int. J. Mol. Sci. 2022, 23, 11363. [Google Scholar] [CrossRef] [PubMed]
  7. Bahnassy, A.A.; Zekri, A.-R.N.; Loutfy, S.A.; Mohamed, W.S.; Moneim, A.A.; Salem, S.E.; Sheta, M.M.; Omar, A.; Al-Zawahry, H. The role of cyclins and cyclin dependent kinases in development and progression of hepatitis C virus-genotype 4-associated hepatitis and hepatocellular carcinoma. Exp. Mol. Pathol. 2011, 91, 643–652. [Google Scholar] [CrossRef]
  8. Ghufran, H.; Azam, M.; Mehmood, A.; Butt, H.; Riazuddin, S. Standardization of diethylnitrosamine-induced hepatocellular carcinoma rat model with time based molecular assessment. Exp. Mol. Pathol. 2021, 123, 104715. [Google Scholar] [CrossRef]
  9. Bas, O.; Sahin, T.K.; Karahan, L.; Rizzo, A.; Guven, D.C. Prognostic significance of the cachexia index (CXI) in patients with cancer: A systematic review and meta-analysis. Clin. Nutr. ESPEN 2025, 68, 240–247. [Google Scholar] [CrossRef]
  10. Na, D.C.; Lee, J.E.; Yoo, J.E.; Oh, B.-K.; Choi, G.H.; Park, Y.N. Invasion and EMT-associated genes are up-regulated in B viral hepatocellular carcinoma with high expression of CD133-human and cell culture study. Exp. Mol. Pathol. 2011, 90, 66–73. [Google Scholar] [CrossRef] [PubMed]
  11. Marumoto, T.; Hirota, T.; Morisaki, T.; Kunitoku, N.; Zhang, D.; Ichikawa, Y.; Sasayama, T.; Kuninaka, S.; Mimori, T.; Tamaki, N.; et al. Roles of aurora-A kinase in mitotic entry and G2 checkpoint in mammalian cells. Genes Cells 2002, 7, 1173–1182. [Google Scholar] [CrossRef]
  12. Varshney, N.; Pandey, R.K.; Mishra, A.; Kumar, S.; Jha, H.C. Aurora Kinase A: Integrating Insights into Cancer, Inflammation, and Infectious Diseases. Gut Microbes Rep. 2024, 1, 2419069. [Google Scholar] [CrossRef]
  13. AURKA Gene—GeneCards. AURKA Protein. AURKA Antibody. Available online: https://www.genecards.org/cgi-bin/carddisp.pl?gene=AURKA (accessed on 15 September 2025).
  14. Magnaghi-Jaulin, L.; Eot-Houllier, G.; Gallaud, E.; Giet, R. Aurora A Protein Kinase: To the Centrosome and Beyond. Biomolecules 2019, 9, 28. [Google Scholar] [CrossRef] [PubMed]
  15. Grisetti, L.; Garcia, C.J.C.; Saponaro, A.A.; Tiribelli, C.; Pascut, D. The role of Aurora kinase A in hepatocellular carcinoma: Unveiling the intriguing functions of a key but still underexplored factor in liver cancer. Cell Prolif. 2024, 57, e13641. [Google Scholar] [CrossRef]
  16. Choudhary, H.B.; Mandlik, S.K.; Mandlik, D.S. Role of p53 suppression in the pathogenesis of hepatocellular carcinoma. World J. Gastrointest. Pathophysiol. 2023, 14, 46–70. [Google Scholar] [CrossRef] [PubMed]
  17. Du, R.; Huang, C.; Liu, K.; Li, X.; Dong, Z. Targeting AURKA in Cancer: Molecular mechanisms and opportunities for Cancer therapy. Mol. Cancer 2021, 20, 15. [Google Scholar] [CrossRef]
  18. Sivasudhan, E.; Blake, N.; Lu, Z.; Meng, J.; Rong, R. Hepatitis B Viral Protein HBx and the Molecular Mechanisms Modulating the Hallmarks of Hepatocellular Carcinoma: A Comprehensive Review. Cells 2022, 11, 741. [Google Scholar] [CrossRef]
  19. Katayama, H.; Sasai, K.; Kawai, H.; Yuan, Z.-M.; Bondaruk, J.; Suzuki, F.; Fujii, S.; Arlinghaus, R.B.; Czerniak, B.A.; Sen, S. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat. Genet. 2004, 36, 55–62. [Google Scholar] [CrossRef]
  20. Macůrek, L.; Lindqvist, A.; Lim, D.; Lampson, M.A.; Klompmaker, R.; Freire, R.; Clouin, C.; Taylor, S.S.; Yaffe, M.B.; Medema, R.H. Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery. Nature 2008, 455, 119–123. [Google Scholar] [CrossRef]
  21. Raab, M.; Matthess, Y.; Raab, C.A.; Gutfreund, N.; Dötsch, V.; Becker, S.; Sanhaji, M.; Strebhardt, K. A dimerization-dependent mechanism regulates enzymatic activation and nuclear entry of PLK1. Oncogene 2022, 41, 372–386. [Google Scholar] [CrossRef]
  22. Park, J.-E.; Soung, N.-K.; Johmura, Y.; Kang, Y.H.; Liao, C.; Lee, K.H.; Park, C.H.; Nicklaus, M.C.; Lee, K.S. Polo-box domain: A versatile mediator of polo-like kinase function. Cell. Mol. Life Sci. 2010, 67, 1957–1970. [Google Scholar] [CrossRef]
  23. Hutterer, A.; Berdnik, D.; Wirtz-Peitz, F.; Žigman, M.; Schleiffer, A.; Knoblich, J.A. Mitotic Activation of the Kinase Aurora-A Requires Its Binding Partner Bora. Dev. Cell 2006, 11, 147–157. [Google Scholar] [CrossRef] [PubMed]
  24. Kumar, S.; Sharma, A.R.; Sharma, G.; Chakraborty, C.; Kim, J. PLK-1: Angel or devil for cell cycle progression. Biochim. Biophys. Acta–Rev. Cancer 2016, 1865, 190–203. [Google Scholar] [CrossRef]
  25. Brodie, K.M.; Henderson, B.R. Characterization of BRCA1 Protein Targeting, Dynamics, and Function at the Centrosome. J. Biol. Chem. 2012, 287, 7701–7716. [Google Scholar] [CrossRef]
  26. Kallioniemi, O.-P. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum. Mol. Genet. 2001, 10, 657–662. [Google Scholar] [CrossRef]
  27. Sarı, S.; Özsoy, E.R. Aurora Kinases: Their Role in Cancer and Cellular Processes. Türk Doğa Ve Fen Derg. 2024, 13, 128–139. [Google Scholar] [CrossRef]
  28. Evers, D.L.; He, J.; Kim, Y.H.; Mason, J.T.; O’Leary, T.J. Paraffin Embedding Contributes to RNA Aggregation, Reduced RNA Yield, and Low RNA Quality. J. Mol. Diagn. 2011, 13, 687–694. [Google Scholar] [CrossRef]
  29. Huang, C.-I.; Wang, C.-C.; Tai, T.-S.; Hwang, T.-Z.; Yang, C.-C.; Hsu, C.-M.; Su, Y.-C. eIF4E and 4EBP1 are prognostic markers of head and neck squamous cell carcinoma recurrence after definitive surgery and adjuvant radiotherapy. PLoS ONE 2019, 14, e0225537. [Google Scholar] [CrossRef]
  30. Yao, L.-J.; Zhong, Z.-S.; Zhang, L.-S.; Chen, D.-Y.; Schatten, H.; Sun, Q.-Y. Aurora-A Is a Critical Regulator of Microtubule Assembly and Nuclear Activity in Mouse Oocytes, Fertilized Eggs, and Early Embryos1. Biol. Reprod. 2004, 70, 1392–1399. [Google Scholar] [CrossRef] [PubMed]
  31. Tsai, M.-Y.; Zheng, Y. Aurora A Kinase-Coated Beads Function as Microtubule-Organizing Centers and Enhance RanGTP-Induced Spindle Assembly. Curr. Biol. 2005, 15, 2156–2163. [Google Scholar] [CrossRef] [PubMed]
  32. Lee, Y.; Wang, J.J.; Zhu, Y.; Agopian, V.G.; Tseng, H.; Yang, J.D. Diagnostic Criteria and LI-RADS for Hepatocellular Carcinoma. Clin. Liver Dis. 2021, 17, 409–413. [Google Scholar] [CrossRef]
  33. European Association for the Study of the Liver. Corrigendum to “EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma [J Hepatol 69 (2018) 182–236]”. J. Hepatol. 2019, 70, 817. [Google Scholar] [CrossRef]
  34. Marrero, J.A.; Kulik, L.M.; Sirlin, C.B.; Zhu, A.X.; Finn, R.S.; Abecassis, M.M.; Roberts, L.R.; Heimbach, J.K. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2018, 68, 723–750. [Google Scholar] [CrossRef]
  35. Singal, A.G.; Llovet, J.M.; Yarchoan, M.; Mehta, N.; Heimbach, J.K.; Dawson, L.A.; Jou, J.H.; Kulik, L.M.; Agopian, V.G.; Marrero, J.A.; et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 2023, 78, 1922–1965. [Google Scholar] [CrossRef] [PubMed]
  36. Gonçalves, E.; Fragoulis, A.; Garcia-Alonso, L.; Cramer, T.; Saez-Rodriguez, J.; Beltrao, P. Widespread Post-transcriptional Attenuation of Genomic Copy-Number Variation in Cancer. Cell Syst. 2017, 5, 386–398.e4. [Google Scholar] [CrossRef] [PubMed]
  37. Koh, H.M.; Jang, B.G.; Hyun, C.L.; Kim, Y.S.; Hyun, J.W.; Chang, W.Y.; Maeng, Y.H. Aurora Kinase A Is a Prognostic Marker in Colorectal Adenocarcinoma. J. Pathol. Transl. Med. 2017, 51, 32–39. [Google Scholar] [CrossRef]
  38. Nishida, N.; Fukuda, Y.; Komeda, T.; Kita, R.; Sando, T.; Furukawa, M.; Amenomori, M.; Shibagaki, I.; Nakao, K.; Ikenaga, M. Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res. 1994, 54, 3107–3110. [Google Scholar] [PubMed]
  39. Lee, J.Y.; Hong, M.; Lee, J.; Lee, S.; Kim, K.-M.; Park, C.; Lim, H.Y. An investigation of the role of gene copy number variations in sorafenib sensitivity in metastatic hepatocellular carcinoma patients. J. Cancer 2017, 8, 730–736. [Google Scholar] [CrossRef]
  40. Zheng, D.; Li, J.; Yan, H.; Zhang, G.; Li, W.; Chu, E.; Wei, N. Emerging roles of Aurora-A kinase in cancer therapy resistance. Acta Pharm. Sin. B 2023, 13, 2826–2843. [Google Scholar] [CrossRef]
  41. Staff, S.; Isola, J.; Jumppanen, M.; Tanner, M. Aurora-A gene is frequently amplified in basal-like breast cancer. Oncol. Rep. 2010, 23, 307–312. [Google Scholar] [CrossRef]
  42. Jeng, Y.-M.; Peng, S.-Y.; Lin, C.-Y.; Hsu, H.-C. Overexpression and Amplification of Aurora-A in Hepatocellular Carcinoma. Clin. Cancer Res. 2004, 10, 2065–2071. [Google Scholar] [CrossRef]
  43. Study Details. NCT00500903. A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants with Advanced Solid Tumors. ClinicalTrials.gov. Available online: https://clinicaltrials.gov/study/NCT00500903 (accessed on 15 September 2025).
  44. Zhang, K.; Wang, T.; Zhou, H.; Feng, B.; Chen, Y.; Zhi, Y.; Wang, R. A Novel Aurora-A Inhibitor (MLN8237) Synergistically Enhances the Antitumor Activity of Sorafenib in Hepatocellular Carcinoma. Mol. Ther. Nucleic Acids 2018, 13, 176–188. [Google Scholar] [CrossRef]
  45. Miralaei, N.; Majd, A.; Ghaedi, K.; Peymani, M.; Safaei, M. Integrated pan-cancer of AURKA expression and drug sensitivity analysis reveals increased expression of AURKA is responsible for drug resistance. Cancer Med. 2021, 10, 6428–6441. [Google Scholar] [CrossRef]
  46. Al-Khafaji, A.S.K.; Marcus, M.W.; Davies, M.P.A.; Risk, J.M.; Shaw, R.J.; Field, J.K.; Liloglou, T. AURKA mRNA expression is an independent predictor of poor prognosis in patients with non-small cell lung cancer. Oncol. Lett. 2017, 13, 4463–4468. [Google Scholar] [CrossRef] [PubMed]
  47. Couch, F.J.; Sinilnikova, O.; Vierkant, R.A.; Pankratz, V.S.; Fredericksen, Z.S.; Stoppa-Lyonnet, D.; Coupier, I.; Hughes, D.; Hardouin, A.; Berthet, P.; et al. AURKA F31I Polymorphism and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: A Consortium of Investigators of Modifiers of BRCA1/2 Study. Cancer Epidemiol. Biomark. Prev. 2007, 16, 1416–1421. [Google Scholar] [CrossRef]
  48. Sasai, K.; Treekitkarnmongkol, W.; Kai, K.; Katayama, H.; Sen, S. Functional Significance of Aurora Kinases–p53 Protein Family Interactions in Cancer. Front. Oncol. 2016, 6, e1002566. [Google Scholar] [CrossRef]
  49. Cai, Q.; Xiao, B.; Si, H.; Cervini, A.; Gao, J.; Lu, J.; Upadhyay, S.K.; Verma, S.C.; Robertson, E.S. Kaposi’s Sarcoma Herpesvirus Upregulates Aurora A Expression to Promote p53 Phosphorylation and Ubiquitylation. PLoS Pathog. 2012, 8, e1002566. [Google Scholar] [CrossRef]
  50. García-Álvarez, B.; de Cárcer, G.; Ibañez, S.; Bragado-Nilsson, E.; Montoya, G. Molecular and structural basis of polo-like kinase 1 substrate recognition: Implications in centrosomal localization. Proc. Natl. Acad. Sci. USA 2007, 104, 3107–3112. [Google Scholar] [CrossRef] [PubMed]
  51. KY, C.; ED, L.; Sinclair, J.; Nigg, E.A.; Johnson, L.N. The crystal structure of the human polo-like kinase-1 polo box domain and its phospho-peptide complex. EMBO J. 2003, 22, 5757–5768. [Google Scholar] [CrossRef]
  52. Liu, Z.; Sun, Q.; Wang, X. PLK1, A Potential Target for Cancer Therapy. Transl. Oncol. 2017, 10, 22–32. [Google Scholar] [CrossRef] [PubMed]
  53. Burt, A.D.; Portmann, B.; Ferrell, L.D.; MacSween, R.N.M. MacSween’s Pathology of the Liver; Churchill Livingstone: London, UK; Elsevier: Amsterdam, The Netherlands, 2012; ISBN 9780702033988. [Google Scholar]
  54. Mou, P.K.; Yang, E.J.; Shi, C.; Ren, G.; Tao, S.; Shim, J.S. Aurora kinase A, a synthetic lethal target for precision cancer medicine. Exp. Mol. Med. 2021, 53, 835–847. [Google Scholar] [CrossRef] [PubMed]
  55. Qi, Z.; Luo, J.; Liu, W.; Xu, Y.; Ma, Y.; Hu, S.; Shen, X.; Du, X.; Xiang, W. Alisertib impairs the stemness of hepatocellular carcinoma by inhibiting purine synthesis. J. Biol. Chem. 2025, 301, 108558. [Google Scholar] [CrossRef] [PubMed]
  56. Zhu, Q.; Luo, M.; Zhou, C.; Zhou, Z.; He, Z.; Yu, X.; Zhou, S. A proteomics-based investigation on the anticancer activity of alisertib, an Aurora kinase A inhibitor, in hepatocellular carcinoma Hep3B cells. Am. J. Transl. Res. 2017, 9, 3558–3572. [Google Scholar]
  57. Lin, X.; Pan, F.; Abudoureyimu, M.; Wang, T.; Hao, L.; Wang, R. Aurora-A inhibitor synergistically enhances the inhibitory effect of anlotinib on hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 2024, 690, 149247. [Google Scholar] [CrossRef] [PubMed]
Diagnostics 16 00160 g001
Figure 1. Agarose gel electrophoresis of RNA isolated from control liver tissue samples.
Figure 1. Agarose gel electrophoresis of RNA isolated from control liver tissue samples.
Diagnostics 16 00160 g001
Diagnostics 16 00160 g002
Figure 2. Immunohistochemical evaluation across study groups. (1a) Control liver tissue demonstrating no AURKA expression. In some cases, weak cytoplasmic staining was observed in pericentral hepatocytes (arrowhead), consistent with localized cellular stress in this region. Arrows indicate areas with focal cytoplasmic positivity. AURKA, ×100. (1b,c) HBV-HCC and Cr-HCC tissues showing moderate-to-strong AURKA positivity with predominant nuclear staining and variable cytoplasmic staining. Cytoplasmic staining is consistent with AURKA involvement in microtubule dynamics during cellular stress and mitotic regulation. AURKA, ×100. (2a) Control tissue negative for p53Ser315, ×100. (2b) HBV-HCC demonstrating moderate and diffuse nuclear p53Ser315 positivity; intratumoral staining heterogeneity observed (arrows), ×100. (2c) Cr-HCC showing strong and diffuse nuclear p53Ser315 staining, ×100. (3a,b) Control and HBV-HCC tissues negative for PLK1Thr210, ×100. (3c) Cr-HCC demonstrating strong and diffuse nuclear PLK1Thr210 staining, ×100. (4a) Control tissue negative for BRCA1, ×100. (4b) HBV-HCC with prominent nuclear BRCA1 staining, ×100. (4c) Cr-HCC with weak and focal nuclear BRCA1 staining, ×100.
Figure 2. Immunohistochemical evaluation across study groups. (1a) Control liver tissue demonstrating no AURKA expression. In some cases, weak cytoplasmic staining was observed in pericentral hepatocytes (arrowhead), consistent with localized cellular stress in this region. Arrows indicate areas with focal cytoplasmic positivity. AURKA, ×100. (1b,c) HBV-HCC and Cr-HCC tissues showing moderate-to-strong AURKA positivity with predominant nuclear staining and variable cytoplasmic staining. Cytoplasmic staining is consistent with AURKA involvement in microtubule dynamics during cellular stress and mitotic regulation. AURKA, ×100. (2a) Control tissue negative for p53Ser315, ×100. (2b) HBV-HCC demonstrating moderate and diffuse nuclear p53Ser315 positivity; intratumoral staining heterogeneity observed (arrows), ×100. (2c) Cr-HCC showing strong and diffuse nuclear p53Ser315 staining, ×100. (3a,b) Control and HBV-HCC tissues negative for PLK1Thr210, ×100. (3c) Cr-HCC demonstrating strong and diffuse nuclear PLK1Thr210 staining, ×100. (4a) Control tissue negative for BRCA1, ×100. (4b) HBV-HCC with prominent nuclear BRCA1 staining, ×100. (4c) Cr-HCC with weak and focal nuclear BRCA1 staining, ×100.
Diagnostics 16 00160 g002
Table 1. Study groups.
Table 1. Study groups.
GroupsHistopathologic Feature
ControlNormal liver tissue. Healthy donor liver sample.Liver wedge biopsy material. TMA generated from paraffin block.
HBV-HCCHBV-associated HCC casesHepatectomy material. TMA paraffin block, generating new tissue microarrays from paraffin block.
Cr-HCCHCC cases that cannot be clinically and serologically associated with any etiology.Hepatectomy material. TMA paraffin block generating new tissue microarrays from paraffin block.
Table 2. Primer sequence (from 3′ to 5′).
Table 2. Primer sequence (from 3′ to 5′).
PrimerPrimer Sequence
AURKA-FGCAACCAGTGTACCTCATCCTG
AURKA-RAAGTCTTCCAAAGCCCACTGCC
36B4-FCAGCAAGTGGGAAGGTGTAATCC
36B4-RCCCATTCTATCATCAACGGGTACAA
Table 3. IHC scoring criteria.
Table 3. IHC scoring criteria.
Staining PrevalenceScoreColor DepthScore
Staining rate of cells 0%0No staining0
Staining rate of cells 1–25%1Weak1
Staining rate of cells 25–50%2Middle 2
Staining rate of cells 50–75%3Strong3
Staining rate of cells 75–100%4——
Table 4. CNV statistical results compared between HBV-HCC and Cr-HCC.
Table 4. CNV statistical results compared between HBV-HCC and Cr-HCC.
VariablesHBV-HCCCr-HCCp Value
Median (Minimum–Maximum)
∆∆Ct6.981 (4.454–9.983)6.181 (3.753–8.11)0.060
2−∆∆Ct0.1 (0.012–0.577)0.174 (0.046–0.938)0.060
Table 5. IHC parameters and statistical analysis.
Table 5. IHC parameters and statistical analysis.
Median (Minimum–Maximum)
VariablesControl GroupHBV-HCCp Value
AURKA0 (0–1)9 (4–12)<0.001 *
P53Ser3151 (0–2)2 (0–6)0.002 ¥
PLK1Thr2101 (0–6)2 (0–8)0.296
BRCA11 (0–2)4 (0–8)0.006 ₫
Control groupCr-HCCp
AURKA0 (0–1)8 (3–12)<0.001 *
P53Ser3151 (0–2)4 (0–9)<0.001 ¥
PLK1Thr2101 (0–6)6 (0–12)<0.001 Ꝋ
BRCA11 (0–2)1 (0–4)0.239
HBV-HCCCr-HCCp
AURKA9 (4–12)8 (3–12)0.224
P53Ser3152 (0–6)4 (0–9)0.025 ¥¥
PLK1Thr2102 (0–8)6 (0–12)0.001 Ꝋ
BRCA14 (0–8)1 (0–4)0.11
Bold values indicate statistically significant differences between the compared groups. *; Control vs. HBV-HCC and Control vs. Cr-HCC, ¥; Control vs. HBV-HCC, ¥¥; HBV-HCC vs. Cr-HCC, Ꝋ; Cr-HCC vs. Control and Cr-HCC vs. HBV-HCC, ₫ ; Control vs. HBV-HCC. A statistically significant increase in AURKA was observed in HBV-HCC and Cr-HCC groups compared to the Control group (p < 0.001 *). There was no significant difference in the high level expression of AURKA between both experimental groups (p = 0.224). Phosphospecific P53Ser315 was elevated in HBV-HCC and Cr-HCC groups and was statistically significant compared to the Control group (p = 0.002 ¥, p < 0.001 ¥, respectively). However, when HBV-HCC and Cr-HCC groups were compared, the high expression of p53Ser315 in HBV-HCC group differed from Cr-HCC group (p = 0.025 ¥¥). Phosphospecific PLK1Thr210 was highly expressed in the Cr-HCC group, differing from the Control group (p < 0.001 Ꝋ) and the HBV-HCC group (p = 0.001 Ꝋ) and this difference was statistically significant. BRCA1 was found to be expressed significantly higher in the HBV-HCC group as a result of statistical analysis (p = 0.006 ₫).
Table 6. Clinical Role of Imaging and Liver Biopsy in the Diagnosis of Hepatocellular Carcinoma.
Table 6. Clinical Role of Imaging and Liver Biopsy in the Diagnosis of Hepatocellular Carcinoma.
Clinical ScenarioRole of Imaging (LI-RADS)Indication for Liver Biopsy
Cirrhotic patient with LI-RADS 5 lesionDiagnosticNot required
Cirrhotic patient with LI-RADS 3–4 lesionIndeterminateMay be required for diagnostic confirmation
Non-cirrhotic patientLimited diagnostic specificityGenerally required
Atypical imaging featuresInsufficient for definitive diagnosisRequired for differential diagnosis
Patients considered for systemic chemotherapyLimited role in treatment selectionMay be required for molecular subclassification or target identification
Patients considered for immunotherapyNot diagnosticMay be required for immunophenotypic profiling (e.g., PD-L1, TME)
Assessment of treatment response or disease progressionPrimary follow-up toolSelected cases only (suspected resistance or transformation)
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Huz, M.; Karadag Soylu, N.; Koc, A.; Kucukakcali, Z.; Danis, N.; Ozhan, O. The Role of Aurora Kinase A in HBV-Associated Hepatocellular Carcinomas: A Molecular and Immunohistochemical Study. Diagnostics 2026, 16, 160. https://doi.org/10.3390/diagnostics16010160

AMA Style

Huz M, Karadag Soylu N, Koc A, Kucukakcali Z, Danis N, Ozhan O. The Role of Aurora Kinase A in HBV-Associated Hepatocellular Carcinomas: A Molecular and Immunohistochemical Study. Diagnostics. 2026; 16(1):160. https://doi.org/10.3390/diagnostics16010160

Chicago/Turabian Style

Huz, Mustafa, Nese Karadag Soylu, Ahmet Koc, Zeynep Kucukakcali, Nefsun Danis, and Onural Ozhan. 2026. "The Role of Aurora Kinase A in HBV-Associated Hepatocellular Carcinomas: A Molecular and Immunohistochemical Study" Diagnostics 16, no. 1: 160. https://doi.org/10.3390/diagnostics16010160

APA Style

Huz, M., Karadag Soylu, N., Koc, A., Kucukakcali, Z., Danis, N., & Ozhan, O. (2026). The Role of Aurora Kinase A in HBV-Associated Hepatocellular Carcinomas: A Molecular and Immunohistochemical Study. Diagnostics, 16(1), 160. https://doi.org/10.3390/diagnostics16010160

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop